



Exubera (Insulin Human [rDNA Origin] Inhalation Powder)

- ◆ **Comprehensive Post-Approval Pharmacovigilance Commitment**
- ◆ **Global Customer-Care Program**
- ◆ **Pfizer Participation in the Public-Health Agenda**
 - **Coalition Approaches to Diabetes Prevention and Treatment**
 - **Public Sector**
 - **Food Industry**
 - **Behavioral Experts**
 - **Clinicians**



Exubera (Insulin Human [rDNA Origin] Inhalation Powder)

- ◆ **Pfizer Committed to Improving the Lives of Patients with Diabetes**
- ◆ **A New-Generation Device to Follow on From Exubera is in Research, Providing:**
 - **Enhanced Medical Profile Allowing Smaller Titration Steps**
 - **Advanced User Conveniences, Easier to Carry During the Day**




Approaches Along the Diabetes Continuum





Approaches Along the Diabetes Continuum



APPROACHES

Weight Loss	Insulin Sensitizers	Improved β Cell Function	Diabetic Complications
CB-1 Antagonists	PPAR α Agonists	DPPIV Inhibitors	
Opioid Receptors			
CCK-A Agonists			
5-HTc Agonists			
11 β HSD Antagonists			
DGAT Inhibitors			
CCR2 Inhibitors			



CVMED R&D

- ◆ **Atherosclerosis**
- ◆ **Obesity**
- ◆ **Diabetes**
- ◆ **Bone and Muscle Health**
- ◆ **Thrombosis**



Bone And Muscle Health Portfolio

Bone

Prevent Bone Loss

- Oporia

Bone Healing

- CP-533,536



Muscle

Chronic Muscle Loss

- Myostatin mAb

Acute Muscle Loss

- Myostatin mAb





Osteoporosis is a Major Public-Health Problem

- ◆ **An Estimated 75 Million Women in the U.S., Europe, and Japan Have Osteoporosis**
- ◆ **One Third of Women Aged 50+ Years Will Have an Osteoporosis-related Fracture**
- ◆ **Direct Medical Costs of Osteoporotic and Associated Fractures Were More Than \$48 Billion in 2002**



Oporia (Lasofoxifene)

Selective Estrogen Receptor Modulator

- ◆ **Non-Approvable Letter Received in 2005**
- ◆ **Assessing Risk/Benefit Profile**
 - **3-Year PEARL Data**
 - **Additional Preclinical Assessments**
- ◆ **Meeting Anticipated with FDA in Early 2007**



Bone Fractures

Medical Need and Current Treatments

◆ Medical Need

- **In the U.S., 6 Million People Experience Bone Fractures, Resulting in About 1 Million Hospitalizations**
- **300,000 Patients Progress to Delayed Union or Nonunion**
- **44,000 Excisions of Bone Lesions, Which Result in Critical-Size Bone Gaps That Fail to Heal**

◆ Current Fracture Treatment Options

- **Casting**
- **Intramedullary Nailing**
- **Pins**
- **Bone Morphogenetic Proteins**



CP-533,536 (Prostaglandin E2 Agonist) Heals Bone Fractures

Osteotomy (Shown at 10 weeks)

X-rays

Vehicle



CP-533536



CT Scans

Vehicle



CP-533536






CP-533,536 (Prostaglandin E2 Agonist) Heals Bone Defects

Critical Defect (Shown at 24 Weeks)


Defect



Vehicle



CP-533536



*Phase 2 Trial will report in early 2007
Phase 3 start possible in late 2007*

- ◆ **Atherosclerosis**
- ◆ **Obesity**
- ◆ **Diabetes**
- ◆ **Bone and Muscle Health**
- ◆ **Thrombosis**



The Unmet Medical Need In Thrombosis

An Ideal Anticoagulant Should Have. . .

Key Attributes

- ◆ Oral Administration
- ◆ Predictability
- ◆ Wide Therapeutic Window
- ◆ No Dose Adjustments
- ◆ No Monitoring
- ◆ Low Risk of Food or Drug Interactions



Potential Advantages

- ◆ Inpatient/Outpatient Use
- ◆ Safe and Effective Anticoagulant
- ◆ Broad Safety/efficacy Range
- ◆ Fixed Doses for Most
- ◆ Reduced Costs
- ◆ Convenient Use Regardless of Diet or Concomitant Meds



Factor Xa Inhibition

- ◆ **Larger Therapeutic Window, Leading to Possibly Greater Separation of Efficacy From Bleeding**
- ◆ **Reduced Bleeding Risk**
- ◆ **Less Risk of Rebound Ischemia After Therapy is Ended (As Demonstrated by Direct Thrombin Inhibitors)**



PD-348,292

Factor Xa Inhibitor

◆ Profile


- Oral, Selective, Direct-Acting Factor Xa Inhibitor
- Suitable for Once-Daily Dosing
- Low Risk of Food or Drug Interactions

◆ Target indications

- Prevention of Venous Thromboembolism in Orthopedic Surgery
- Treatment and Secondary Prevention of Venous Thromboembolism
- Prevention of Thromboembolic Events in Patients With Atrial Fibrillation





Pharmacokinetic/Pharmacodynamic Modeling for Dose Selection





Development Portfolio Focused on Risk-Factor Modification and Disease Intervention

Health Maintenance	Risk-Factor Modification	Disease Intervention
<p>Healthy Aging Population</p>	<p>CP-945,593 Obesity </p>	<p> Phase 3/Registration</p>
	<p>MTPi* Obesity</p> <p>PPARα Lipid/IR</p> <p>DPPIV Diabetes</p>	<p>CP-533,536* Bone Healing</p> <p>PD-348,592* Thrombosis</p> <p>Esperion CV</p> <p>Peg GH GH Deficiency</p>
	<p>μ opioid Obesity</p> <p>11β HSD Diabetes</p> <p>Torcetrapib HDL</p> <p>Combos Obes & DM</p> <p>CCKa Obes & DM</p> <p>PPARα Lipid/IR</p> <p>CETPi HDL</p>	<p>PDE5i CV</p> <p>Phase 1</p> <p>* = new disclosure</p>